🧩Solve the latest #KidneyKolumns crossword: NEPHRONS & NEOPLASIA 🦀🫘Test your knowledge of Onconephrology! 🌟First 5 correct entries will receive a shout-out in the next edition of @isn-india.bsky.social Newsletter Kidney Kolumns 🔗https://puzzel.org/en/crossword/play?p=-OvuDKCWauB8uMBaYYMQ

And @nejm.org retracts ADVOCATE based on the FDA uncovering and 2 academic authors asking for article to be pulled. (Good on them!) www.nejm.org/doi/10.1056/... h/t @drjmluther.bsky.social #Avacopan #vasculitis

Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609. | NEJM

The two academic authors of the article by Jayne et al., Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609,1 request retraction of the article because, accordi...

nejm.org

Swapnil Hiremath 🍁🇨🇦@hswapnil.medsky.social · last mo.

With link this time www.medscape.com/viewarticle/...

#NephJC Consensus From GEMRITUX, MENTOR, STARMEN, RI-CYCLO & MAJESTY- the signal remains consistent: ✅ Anti-CD20 therapy works ✅ Remissions are durable ✅ Relapses are lower than CNIs Check out anti-CD20 trials in pMN by @nephroseeker.medsky.social 👇 #NephJC #TenPostNephJC #NephTwitter #NephSky

Among participants with rifampicin-resistant tuberculosis, a 6-month treatment strategy consisting of bedaquiline, linezolid, delamanid, and levofloxacin or clofazimine was noninferior to the standard treatment. Full phase 3 BEAT Tuberculosis trial results: https://nej.md/4w7aekw

🚨New 🩳 by @nephroseeker.medsky.social eGFRcr, eGFRcys, eGFRcr-cys, mGFR... What does mGFR teach us about estimates and outcomes? #NephSky #MedSky #NephJC www.nephjc.com/news/2026/short/measuredgfr

NephJC Short: The map and the territory: what measured GFR teaches us about our estimates — NephJC

Is measured GFR more accurate than eGFR for forecasting adverse outcomes?

nephjc.com

Took us more than 10 years to get this to this stage AVF versus catheters - doing an RCT was difficult and we learnt a lot. Hope our community also does?

Comparing Catheters to Fistulas in Older Patients Starting... : Journal of the American Society of Nephrology

recommendations were based is observational with potential for bias. Methods A pilot randomized controlled trial was conducted in 12 hemodialysis centers in Canada and Australia. Individuals aged 55…

journals.lww.com

Quantitative Serological Detection of NELL1 Autoantibodies in Membranous Nephropathy - Kidney International www.kidney-international.org/article/S008...

Quantitative Serological Detection of NELL1 Autoantibodies in Membranous Nephropathy

Membranous nephropathy (MN) comprises distinct subtypes driven by autoantibodies targeting podocyte-associated proteins, one of which is neural EGFL like 1 (NELL1). Currently, the diagnosis of NELL1-a...

kidney-international.org

Probenicid affects urate pathway and decreasing cyst growth in ADPKD Waiting to see how this area evolves in the future ! Dr Fouad Chebib is an inspiration..changing the landscape of ADPKD treatment!

Jim Myers@kidneystories.bsky.social · 2mo ago

Researchers identify new kidney pathway with help from 1940s-era drug, may improve ... - goo.gl/alerts/GA5qn1 #GoogleAlerts

Huge effect of mTOR inhibition (sirolimus, everolimus?) in tuberous sclerosis academic.oup.com/ckj/article/... in @ckj-era.bsky.social Not an RCT of course - rare disease and all that! Via @dguerrot.bsky.social on LI #NephSky

Real-world management of tuberous sclerosis complex–associated renal angiomyolipomas: the impact of mTOR inhibitors

ABSTRACTBackground. Renal angiomyolipomas (AMLs) drive substantial morbidity in tuberous sclerosis complex (TSC) through haemorrhage and repeated invasive

academic.oup.com

Unlike COMPASS, TRACK demonstrates rivaroxaban doesn’t have the same CV benefit in CKD jamanetwork.com/journals/jam... Simultaneous pubs from #ERA26

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease

This randomized clinical trial examines the safety and efficacy of low-dose rivaroxaban in the treatment of patients with advanced chronic kidney disease at high risk for cardiovascular events.

jamanetwork.com

Simulpub number 6 at #ERA26 Obi beats tacrolimus in membranous nephropathy www.nejm.org/doi/full/10.... in NEJM No surprise after MENTOR

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy | NEJM

Studies of obinutuzumab, a type II anti-CD20 antibody, have shown efficacy in the treatment of hematologic cancers and autoimmune diseases. An evaluation of the efficacy and safety of obinutuzumab ...

nejm.org

21/F G3P0LOA2 14weeks POG. Two 1st trimester abortions-cause? Incidental detection of urine alb. No HT 24 HR UP =1.3g/d s.creat=0.7 mg/dL Urine- no RBCs APLA,ANA negative, C3, C4 normal. Wud u do a biopsy ? #NephSky @shilpajesudason.bsky.social @silvishah.bsky.social @priti899.bsky.social

✨Exciting news #NephtSky The new #NephJC editorial interns are here! 📢Give them a follow and make them feel at home 👉 @drbarbateba.bsky.social @ancast13.bsky.social @kiddokidney.bsky.social @andrewdelaat.bsky.social @farahwehbe92.bsky.social 👇👇 www.nephjc.com/news/2025/6/...

NephJC Internship 2026-2027 — NephJC

Introducing NephJC’s brand new editorial internship class of 2026-2027

nephjc.com

1/10 Welcome to #TenPostNephJC Can we move beyond slowing CKD → to actually repairing the kidney? Last #NephJC we discussed Rilparencel, a renal autologous cell therapy (REACT) infusion and its effect on eGFR slope.

Hi everyone! Pallavi from New Delhi. No COI #NephJC Using flozins occasionally in transplants-mostly in those with proteinuria+-PTDM.

moving on from IgAN to FSGS: BI 764198 a TRPC6 inhibitor reduces proteinuria in an N = 67 phase 2 RCT www.thelancet.com/journals/lan... in @thelancet.com #NephSky

TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198

BI 764198 lowered proteinuria and was well tolerated by participants in this trial. This is the first evidence of efficacy with a podocyte-targeted therapy in FSGS. Larger randomised controlled trials...

thelancet.com

Editors’ Choice 2025: Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial This phase 2 trial tested ravulizumab, a complement C5 inhibitor, in adults with IgA nephropathy. Check out the paper here: kidney.pub/JASN0534

Sodium-Glucose Cotransporter-2 Inhibitors #SGLT2i and #Cardiorenal Events in #Nonalbuminuric Kidney Disease #VisualAbstract by Augusto Cesar S Santos Jr https://www.kireports.org/article/S2468-0249(25)00774-0/fulltext @cwhuang0824

1/10 Last #NephJC we discussed Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN #TenPostNephJC Given the central role of complement dysregulation in C3 glomerulonephritis, we assessed whether complement-targeted therapies confer therapeutic benefit. www.nejm.org/doi/full/10....

Hi everyone! Pallavi from New Delhi. No COI #NephJC

Check out the VA for VALIANT from @nephromommy-akshu.bsky.social #NephJC www.nephjc.com/news/2026/1/11/valiant-the-visual-abstract

VALIANT: The Visual Abstract — NephJC

The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-com...

nephjc.com

The LIBERATE-D VA by @sejalplakhani.bsky.social Should we break the pattern of thrice weekly dialysis in AKI-D? #NephJC #NephSky www.nephjc.com/news/liberateva

LIBERATE-D: The Visual Abstract — NephJC

In patients with dialysis-dependent acute kidney injury, a conservative dialysis strategy was evaluated in the LIBERATE-D trial. Could less be more? Join the discussion in #NephJC, but first, check ou...

nephjc.com

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳 How soon should we withhold dialysis in AKI? We're discussing the LIBERATE-D trial #NephSky This one might just change your mind 🧠🧠 Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social www.nephjc.com/news/liberated-aki

Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D — NephJC

This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

nephjc.com

1/10 Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC Read the article 👇 www.nejm.org/doi/10....

T3f: #NephJC Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA). Do you think either has the advantage?

T0k: #NephJC The 96-week extension demonstrated durability: ⬇️proteinuria fell 52% ⬇️Gd-IgA1 dropped 66% ⬇️hematuria declined 75% ⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m² ⚠️Safety: mild injection-site reactions and transient infections pubmed.ncbi.nlm.nih....

Hi everyone! Pallavi from New Delhi ! The day light saving change in #NephJC doesn't help when in India - approaching time to leave for work..will be lurking . Excited about targeted therapeutic approaches in IgAN . No COI.

Day light saving always confuses me. One hour early for #NephJC 🥲 and wondering where everyone else is! 😂

Check out the awesome visual abstract by @salinesolut.bsky.social Attacking the origins of IgAN with atacicept ⚔️ www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract

ORIGIN-3: The Visual Abstract — NephJC

Atacicept, BAFF/APRIL inhibition in IgAN

nephjc.com

APRIL/BAFF inhibition: 🎯💊🩺 Trials are under way on this pathway, which promise to get to the root cause of IgAN. However, with great innovation comes…greater confusion. Sequence of treatment, cost, and side effects will need to be considered when increasing immunosuppression. #NephJC